Table 1 Patients and disease characteristics at baseline

Men

6 (60%)

Age (year)

37.3 ± 12.8

Smoking status

Active smoker

3 (30%)

Non-smoker

3 (30%)

Former smoker

4 (40%)

BMI^†

24.4 ± 5

CD^‡ duration (year)

11.8 ± 11.4

CDAI^§ score

139 ± 116

SIBDQ^†† score

43 ± 12

Fistula duration (year)

5.2 ± 4.9

PDAI^‡‡ score

7.3 ± 2.7

Number of fistula tract

1

4 (40%)

2

5 (50%)

 > 2

1 (10%)

Type of fistula

Intersphincteric

1 (10%)

Trans-sphincteric

8 (80%)

Suprasphincteric

0 (0%)

Extrasphincteric

1 (10%)

History of fistula surgery

10 (100%)

Prior fistula treatment failure

At least 1 anti-TNFα^§§ (± IS^†††)

10 (100%)

2 anti-TNFα

8 (80%)

Vedolizumab

3 (30%)

Derivation ileostomy

2 (20%)

Baseline treatment

Anti-TNFα

7 (70%)

Vedolizumab

3 (30%)